For the nine months ended September 2026 (FY2026 Q3), consolidated revenue was 573 million yen (Year-over-Year +45.1%), operating loss was 1,532 million yen, and quarterly net loss attributable to owners of parent was 1,633 million yen. Full-year guidance is revenue 720 million yen, operating loss 2,028 million yen, and net loss 2,090 million yen. The drug discovery segment recorded substantial losses due to increased clinical development costs, while the drug discovery support segment achieved revenue of 573 million yen (YoY +45.1%) and operating income of 82 million yen. Shareholders’ equity is significantly negative, posing a risk of insolvency. The financial summary includes a note on material uncertainties related to the going concern assumption.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4572-20261106-01.pdf","jir_short_summary":"For the nine months ended September 2026 (FY2026 Q3), consolidated revenue was 573 million yen (Year-over-Year +45.1%), operating loss was 1,532 million yen, and quarterly net loss attributable to owners of parent was 1,633 million yen. Full-year guidance is revenue 720 million yen, operating loss 2,028 million yen, and net loss 2,090 million yen. The drug discovery segment recorded substantial losses due to increased clinical development costs, while the drug discovery support segment achieved revenue of 573 million yen (YoY +45.1%) and operating income of 82 million yen. Shareholders' equity is significantly negative, posing a risk of insolvency. The financial summary includes a note on material uncertainties related to the going concern assumption.","jir_summary":"### Key Points of the Results\nThe drug discovery segment continued clinical trial progress in the U.S. and pipeline initiatives aimed at out-licensing BTK inhibitors and securing large contracts. However, increased clinical development expenses in the drug discovery segment led to an expanded operating loss, while the drug discovery support segment achieved revenue growth domestically and internationally. The full-year forecast assumes revenue of 720 million yen, operating loss of -2,028 million yen, and net loss attributable to owners of parent of -2,090 million yen. The financial summary notes material events related to the going concern assumption, including cash flow constraints and the possibility of insolvency.\n\n### Outlook and Capital Measures\nThe company is advancing U.S. clinical trials for the BTK inhibitor docirbrutinib with the aim of achieving out-licensing within 2026. Key measures include obtaining upfront payments and milestones from out-licensing the pipeline and securing funds through the drug discovery support business. For financing, the company has issued multiple series of bonds with warrants and executed new share issuances to supplement cash on hand; however, resolving the capital deficit depends on pipeline progress and exercise of new shares.","jir_financial_highlights":"Revenue (consolidated): 573 (Year-over-Year +45.1%)\nOperating loss: -1,532 (Loss at approximately the same level as the prior period)\nQuarterly net loss attributable to owners of parent: -1,633 (Increase from the prior period)\nTotal assets: 1,302 (Increase from the prior period)\nEquity ratio: -69.2 (Significant decline from the prior period)","jir_category":"","jir_hashtags":"#CarnaBiosciencesEarnings, #DrugDiscovery, #DrugDiscoverySupport, #Fundraising, #InsolvencyRisk","jir_key_figures":"Revenue: 573 million yen\nOperating loss: -1,532 million yen\nQuarterly net loss attributable to owners of parent: -1,633 million yen","jir_meta_title":"Carna Biosciences, Inc. Q3 Financial Summary for FY2026\uff5cTrends in Drug Discovery and Support Businesses","jir_meta_description":"Key points from Carna Biosciences, Inc.'s Q3 FY2026 financial summary: revenue 573 million yen (YoY +45.1%), operating loss 1,532 million yen, net loss 1,633 million yen. Drug discovery incurred higher clinical costs while support services remained solid. Material uncertainties regarding going concern noted.","jir_og_title":"Carna Biosciences Earnings\uff5cFY2026 Q3 Financial Summary","jir_og_description":"Carna Biosciences, Inc.'s Q3 results: revenue 573 million yen, operating loss 1,532 million yen, net loss 1,633 million yen. The company is pursuing out-licensing and partnerships while strengthening financial position through fundraising.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/12\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[395,573]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Loss Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/12\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating loss\\\",\\\"data\\\":[-1551.9,-1532.5]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Drug Discovery Support Segment Revenue by Region\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic\\\",\\\"North America\\\",\\\"Europe\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[149,189,87,148]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profitability\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Drug Discovery Support\\\",\\\"Drug Discovery\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Profit\\\",\\\"data\\\":[82985,-1615437]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Comparison of Guidance and Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating profit\\\",\\\"Net profit\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Guidance\\\",\\\"data\\\":[720,-2028,-2090]},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[573,-1532,-1633]}]},\\\"options\\\":{}}\"}]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-143729","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n